Discover

Back to filter

Related topics

Pretargeted delivery of PI3K/mTOR small-molecule inhibitor–loaded nanoparticles

Spectral Instruments Imaging

Jun 23, 2021

Overactivation of the PI3K/mTOR signaling has been identified in non-Hodgkin’s lymphoma....

Top 10 Pharma companies have chosen CYTEK for their flow cytometry facility

Cytek Biosciences

Jun 21, 2021

6 of Top 10 Pharma Companies (Based on total group revenues) have chosen CYTEK - full...

Elevated NSD3 histone methylation activity drives squamous cell lung cancer

Spectral Instruments Imaging

Jun 8, 2021

This work identifies NSD3 as a principal 8p11-12 amplicon-associated oncogenic driver in...

A subset of cytotoxic effector memory T cells enhances CAR T cell efficacy in a model of pancreatic

Tonbo Biosciences

May 21, 2021

Tonbo Biosciences flow cytometry reagents & antibodies are manufactured with the highest...

IncuCyte webinar recording: How to measure Immune Cell Killing of Tumor Cells effectively

Sartorius

May 19, 2021

Immuno-oncology (IO) has transformed cancer treatment. The number of treatments in the IO...

White Paper: Immunophenotyping Rare Immune Cells with Laminar Wash AUTO System

Curiox

May 18, 2021

The Laminar Wash (LW) AUTO system consists of a wall-less plate and a laminar flow cell...

Show all topics (10)

Red-shifted firefly luciferase optimized for Candida albicans in vivo bioluminescence imaging

Sep 15, 2017

The authors of this study attempted to compare the performance of BLI in the present study with that published using the systemic infection model and light detection in the region of the kidneys. They estimated that a lower limit of detection for BLI (50 photon/s/mm2) corresponded to of about 200 CFU/kidney with the instrumentation used here (in-vivo Xtreme II). Given numbers published by Jacobsen et al. (2014) (100 photon/s/mm2 for 3,600 CFU/kidney), this suggests that the method used here increases at least by 4- to 8-fold the sensitivity of C. albicans detection.
This performance can be attributed to several factors including (i) the type of luciferase used (Mut2 has better tissue penetration capacities than the wild type luciferase) and (ii) technical differences provided by the luminescence acquisition of instruments. This performance is even more remarkable when taking in account that BLI data was collected here from animals contained in Sealed Optical Imaging Trays, which may create another obstacle of emitted light to the high sensitivity camera.

Read more

Scientific paper
Technical breakthrough
Application

Brand profile

Bruker Biospin

Bruker is a performace leader in preclinical imaging instrumentation. Bruker offers nine imaging modalities: PET, SPECT, CT, MRI, MPI, fluorescence, luminiscence, radioisotipic imaging and X-ray.

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey